Inter-ethnic differences in xenobiotic metabolism.
暂无分享,去创建一个
[1] B. Henderson,et al. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. , 1994, Journal of the National Cancer Institute.
[2] P. Meredith,et al. Racial differences in drug responses--a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans. , 1986, British journal of clinical pharmacology.
[3] J. Moncrieff,et al. Non-correlation between Debrisoquine and Metoprolol Polymorphisms in the Venda , 1989, Human toxicology.
[4] F. Flores-Murrieta,et al. Pharmacokinetics of Oral Nifedipine in Different Populations , 1993, Journal of clinical pharmacology.
[5] B D Kahan,et al. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability , 1992, Clinical pharmacology and therapeutics.
[6] A G Renwick,et al. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine , 1993, Clinical pharmacology and therapeutics.
[7] R. Rubin,et al. Haloperidol and prolactin concentrations in Asians and Caucasians. , 1988, Journal of clinical psychopharmacology.
[8] M. Ingelman-Sundberg,et al. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. , 1992, Pharmacogenetics.
[9] W. Satariano,et al. Racial differences in cancer incidence: The significance of age‐specific patterns , 1988, Cancer.
[10] B. Ketterer. Effects of genetic polymorphism and enzyme induction in the glutathione S-transferase family on chemical safety and risk assessment. , 1996, Environmental toxicology and pharmacology.
[11] V. Mathan,et al. Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. , 1989, Gut.
[12] J. Miners,et al. Drug glucuronidation in humans. , 1991, Pharmacology & therapeutics.
[13] A. Renwick. Data-derived safety factors for the evaluation of food additives and environmental contaminants. , 1993, Food additives and contaminants.
[14] D. Jacobs,et al. Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. , 1990, American journal of public health.
[15] L Aarons. Population approaches/sparse data analysis for human variability in kinetics and dynamics. , 1996, Environmental toxicology and pharmacology.
[16] M. Eichelbaum,et al. Dissociation of co‐regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians , 1985, Clinical pharmacology and therapeutics.
[17] G. Wilkinson,et al. Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population. , 1990, British journal of clinical pharmacology.
[18] B. Pasternack,et al. Expression of the CYP1A1 gene in peripheral lymphocytes as a marker of exposure to creosote in railroad workers. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[19] A. S. Gross,et al. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.
[20] R. Branch,et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.
[21] L F Prescott,et al. Inter-subject and ethnic differences in paracetamol metabolism. , 1986, British journal of clinical pharmacology.
[22] Margaret Wood,et al. Ethnic differences in response to morphine , 1993 .
[23] F. Gonzalez,et al. Molecular genetics of the P-450 superfamily. , 1990, Pharmacology & therapeutics.
[24] A. Renwick,et al. Ethnic differences in the pharmacokinetics of oral nifedipine. , 1991, British journal of clinical pharmacology.
[25] T. Ishizaki,et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.
[26] C. Pui,et al. Thiopurine methyltransferase activity in American white subjects and black subjects , 1994, Clinical pharmacology and therapeutics.
[27] W. Kalow. Interethnic variation of drug metabolism. , 1991, Trends in pharmacological sciences.
[28] W. Kalow. Pharmacogenetics of drug metabolism , 1980 .
[29] W. Kalow,et al. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. , 1985, British journal of clinical pharmacology.
[30] E. Taioli,et al. Relationship between genotype and function of the human CYP1A1 gene. , 1993, Journal of toxicology and environmental health.
[31] O. Lockridge. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. , 1990, Pharmacology & therapeutics.
[32] D. Evans,et al. Genetic polymorphism and interethnic variability of plasma paroxonase activity. , 1976, Journal of medical genetics.
[33] M. Relling,et al. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. , 1993, The Journal of clinical investigation.
[34] R. Branch,et al. Genetic polymorphism of S-mephenytoin hydroxylation. , 1989, Pharmacology & therapeutics.
[35] A. Renwick,et al. Factors affecting the absolute bioavailability of nifedipine. , 1995, British journal of clinical pharmacology.
[36] D. W. Robin,et al. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. , 1996, British journal of clinical pharmacology.
[37] M. Relling,et al. Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities , 1992, Clinical pharmacology and therapeutics.
[38] G. Tucker,et al. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. , 1992, Pharmacogenetics.
[39] G R Wilkinson,et al. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. , 1989, The New England journal of medicine.
[40] W. Kalow,et al. Thiopurine S‐methyltransferase activity in a Chinese population , 1993, Clinical pharmacology and therapeutics.
[41] R. Hoover,et al. Lung cancer, race, and a CYP1A1 genetic polymorphism. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[42] Honghao Zhou,et al. Ethnic Differences in Drug Disposition and Responsiveness , 1991, Clinical pharmacokinetics.
[43] A. Renwick,et al. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. , 1995, British journal of clinical pharmacology.